Apernavec

Preclinical

UUniversity Hospital, Toulouse

Apernavec is one of 3 therapeutic programs targeting Lymphedema. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

LymphedemaNot yet recruiting

LymphedemaPreclinical

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Lymphedema

#DrugCompanyPhaseTrials

Acebilustat

SStanford University

Phase 2

1 2

GLP-1 Receptor Agonists

JJinling Hospital, China

Phase 1

1 3

Apernavec

UUniversity Hospital, Toulouse

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalNot yet recruiting

Lymphedema

NCT07793656

Clinical

Trials by Indication[1]

Lymphedema1 trial

mRNA Therapy to Restore Lymphatic Flow in Secondary Lymphedema

Not yet recruiting·UUniversity Hospital, Toulouse·Preclinical·NCT07793656·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Apernavec. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Apernavec. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University Hospital, Toulouse company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Toulouse

Apernavec

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Lymphedema1 trial

References

Drug Info

Quick Facts

Related News